
Analysis of Radiofrequency Ablation of Small Renal Tumors in Patients at High Anesthetic and Surgical Risk: Urologist Experience with Follow-up Results in the Initial Six Months

Mehmet Bilgehan Yuksel¹, Ayhan Karakose², Bilal Gumus¹, Serdar Tarhan³, Yusuf Ziya Atesci², Zafer Akan⁴*¹

Abstract

**Background**: To evaluate the results of various types of radiofrequency ablation (RFA) treatment of renal tumors in patients with excessive anesthetic and surgical risk.  
**Materials and Methods**: Data for RFA performed in high risk patients were retrospectively evaluated. Other RFA applications in patients with no anesthetic and/or surgical risk were excluded. RFA was by ultrasound or CT guided percutaneous (USG/CT-PRFA) and retroperitoneally or transperitoneally laparoscopic (RT-LRFA) techniques under general or local anesthesia. Follow-up data of enhanced CT or MRI after 1, 3 and 6 months were analysed for twelve RFA applications.  
**Results**: The RFA applications included 4 (40%) left-sided, 5 (50%) right-sided and 1 (10%) bilaterally RFA (simultaneously 1 right and 2 left). The localizations of tumors were 2 (16.6%) upper, 5 (41.6%) mid and 5 (41.6%) lower pole. The RFA applications included 9 (75%) USG-PRFA, 1 (8.3%) CT-PRFA, 1 (8.3%) T-LRFA and 1 (8.3%) R-LRFA. The mean age was 65.3±8.5 (52-76) years. The mean tumor size was 29.6±6.08 (15-40) mm. No complications related to the RFA were encountered in any of the cases. Failure (residual tumour) was determined in 8.3% (1/12) of USG-RFA application. The success rate was thus 91.7% (11/12). Other 1st, 3rd and 6th months follow-up data revealed no residua and recurrence.  
**Conclusions**: RFA application appears to be safe as a less invasive and effective treatment modality in selected cases of small renal tumors in individuals with excessive anesthetic and also surgical risk.

**Keywords**: Endourology - small renal mass - radiofrequency ablation - excessive anesthetical - surgical risk

Asian Pac J Cancer Prev, 14 (11), 6637-6641

Introduction

Currently, more frequently use of imaging modalities in the observation of disorders resulted in an increased incidence and incidentally diagnosis of small renal masses (SRMs), which are commonly with slow growth, low tumor stage and limited to the kidney (Campbell et al., 2009; Ljungberg et al., 2010; Iannuccilli et al., 2012). For a long time, radical nephrectomy (RN) was accepted as the gold standard treatment for all stages of renal tumors (Huang et al., 2006; Lucas et al., 2008). This management seems to be an overtreatment for some of localized renal tumors, thus the use of nephron-sparing surgery (NSS) increased in the treatment of SRMs as a result of the technological developments and advances in surgical techniques. In the following time, partial nephrectomy (PN) is accepted as the new gold standard in the treatment of SRMs (Campbell et al., 2009; Ljungberg et al., 2010; Breau et al., 2011). Although NSS provides similar functional and oncological results to RN, it has also increased rate of perioperative complications and morbidity especially in elderly patients with multiple comorbidities and high surgical risk (Fergany et al., 2000; Gill et al., 2007; Breau et al., 2011).

Since more SRMs are diagnosed in elderly patients with medical comorbidities, NSS has increased perioperative risk, and the advancements occured in imaging modalities, the use of ablative treatment techniques including radiofrequency ablation (RFA) increased in the treatment of SMRs (Wingo et al., 2008; Ljungberg et al., 2010; Iannuccilli et al., 2012). These minimally invasive, more conservative and nephron-sparing treatment modalities provide some advantages, such as not requiring surgical approach and pedicule clamping, not causing transient ischemia related renal injury, shorter hospital stay, lower complication rate, and offering curative and nephron-
sparing treatment to the patients who are not appropriate candidates for NSS (Matsumoto et al., 2005; Pasticier et al., 2006; Gill et al., 2007; Tracy et al., 2010; Kim et al., 2012, Laguna et al., 2012; Karam et al., 2013).

In this study, we aimed to analyse the results of various types of RFA applications in only the patients who had the excessive anesthetical and also surgical risk and thus could not undergo any curative surgical treatment alternatives, general anesthesia, or the anesthesia with a long duration and to present the urologists’ experience in RFA treatment with the follow-up data of initial six months in this specific indication.

Materials and Methods

The data of patients who had a SRM with the suspicion of renal cell carcinoma on imaging modalities, had the excessive anesthetical and also surgical risk and thus could not undergo any curative surgical treatment alternatives and/or general anesthesia, and underwent RFA application with a local or general anesthesia in a short duration were retrospectively evaluated. Other RFA applications that were performed in patients with no anesthetical and/or surgical risk were excluded from the study. All SRMs were preoperatively diagnosed by the imaging modalities of contrast-enhanced CT or MRI. Although a curative surgical treatment was planned in these patients, some reasons including solitary kidney tumors, bilateral renal tumors, advanced age, coexistent morbidities that significantly increase the risk of anesthesia, no ability for the application of general anesthesia or the anesthesia with a long duration and no ability for the application of a curative surgery or the surgery with a long duration as a result of high surgical and anesthetical risk, and patient preference caused to prefer RFA as a curative treatment. All patients were preoperatively informed, and an informed consent form was obtained. Commonly, posterior and posterolateral tumors were managed by percutaneous technique, and anteriorly and medially located tumors were treated by the laparoscopic approach. RFA application was performed by using RITA model 1500X radiofrequency generator and Starbust Talon radiofrequency probe, which can ablate all parts of the tumor by peripherally opening arms and has the features of self-contained cooling and providing impedance controlled intermittent pulse (Figure 1). Maximal duration of the ablation was 12 minutes, and the ablation cycle was repeated when the targeted temperature was suboptimal.

In percutaneous RFA (PRFA) application, the patient was positioned in a modified lateral position based on tumor location. PRFA was performed in the guidance of ultrasound (USG-PRFA) or CT (CT-PRFA) under general or local anesthesia with sedation. After the determination of the location, borders and the relation with adjacent structures of tumor by the guidance of USG or CT, a perioperative renal biopsy was commonly performed. Subsequently, RFA needle with appropriate tip to the tumor size was inserted into the tumor, and the side arms was opened under direct visualisation of radiological modalities, and the tumor was completely ablated (Figure 2). When it was supposed that an incomplete ablation was present in some patients related to the tumor location and size, synchronous repeated ablation was performed to completely ablate the tumor by repositioning of the RFA needle. Nevertheless, the repeated placement of RFA needle in an appropriate area was more difficult because of the hyperechogenicity of ablation side, which disrupted the clearance of perioperative radiological view (Figure 3).

In laparoscopic RFA (L-RFA) application, transperitoneal (TL-RFA) (Figure 4) and retroperitoneal (RL-RFA) (Figure 5) approaches were used. Both techniques were performed by using 3 ports under general anesthesia. The Gerato fascia and perirenal fatty tissue were dissected, and the tumor was exposed. After the visualisation of tumor by laparsocopic view and synchronous external USG imaging, RFA needle was directly placed into the tumor from the nearest abdominal wall and through the hole of laparoscopic port.
A peroperative renal biopsy was commonly performed. We could not use an intraoperative laparoscopic USG because of not being present. When an incomplete ablation was supposed, synchronous repeated ablation was performed to completely ablate the tumor by repositioning of the RFA electrode. After the completion of ablation, it was seen that the surface of tumor was also ablated.

In the follow up protocol, an enhanced CT or MRI was performed at 1st, 3rd and 6th month. At 1st month control, the determination of an enhancing tumor field was accepted as the presence of residual tumor and incomplete ablation, which meant that the failure of RFA application. Subsequent RFA application was performed in these cases. The presence of being ablated, unenhancing, necrotic tumor field was evaluated as the successfull RFA procedure. Recurrence was defined as the determination of enhancing tumor field at the subsequent controls in patients with no residua at first control.

Results

The data of twelve RFA applications were performed in only the patients with excess anesthesetical and surgical risk. 4 symptomatic tumors presented flank pain and 6 non-sympotmatic tumors were incidentally diagnosed by radiological analysis that was used to evaluate other disorders. The mean age was 65.3±8.5 (52-76) years. The mean tumor size was 29.6±6.08 (15-40) mm. Nine patients had unilateral tumor, and one 1 patient had bilaterally localized, 5 synchronous tumors (1 right and 2 left sided one). The distribution of the localization of tumors were 2 (16.6%) upper, 5 (41.6%) mid and 5 (41.6%) lower pole. The anesthesia type included 9 general and 1 local anesthesia. PRFA applications consisted of 9 (75%) USG-PRFA and 1 (8.3%) CT-PRFA. LRFA applications contained 1 (8.3%) T-LRFA and 1 (8.3%) R-LRFA. The majority of RFA applications consisted of USG-PRFA application. The RFA applications included 4 (40%) left-sided, 5 (50%) right-sided and 1 (10%) bilaterally (simultaneously 1 right and 2 left sided). Technical success was achieved in 11 of 12 (91.7%) initial RFA applications. All of the pre-RFA biopsies demonstrated renal cell carcinoma. No perioperative and postoperative RFA related complications was seen. The data of 1st, 3rd and 6th months’ follow-up results revealed that incomplete tumor ablation was observed in 1 of 10 PRFA, but all of the LRFA applications had no residual tumor at 1st month control. In overall, the failure rate of the initial RFA was 8.3% (1/12), and it was occurred in only 1 USG-RFA application. In this case, USG-RFA was repeated and the patient was subsequently followed according to the same protocol. The 1st month control of secondary RFA application showed no residual tumor, furthermore other controls revealed also no tumor recurrence. In overall, tumor recurrence was not observed in 3rd and 6th month controls of all patients.

Discussion

In 1997, Zlotta et al. initially described the clinical application of RFA in the treatment of SRMs (Zlotta et al., 1997). RFA provides an anti-tumor effect, which occurs as a result of the coagulation necrosis that performs irreversible tissue damage (Campbell et al., 2007). In current RFA systems, the ablative temperature is provided by alternating of radiofrequency energy to the heat, and a coagulative necrosis that radiates outwards from the needle occurs (Hacker et al., 2006; Okhunov et al., 2012).

RFA has some advantages, such as less complication rates, shorter hospital stay and recovery period, not requiring pedicle clamping and causing ischemic renal damage, the applicability as a curative and nephron sparing approach in patients who are not appropriate candidates for surgical treatment. These factors increased the routinely use of RFA in clinical practice. Nevertheless, the most important disadvantage is incomplete tumor ablation and the residua (Matsumoto et al., 2005; Ljungberg et al., 2010; Iannuccilli et al., 2012; Laguna et al., 2012).

In this study, we aimed to analyse the results of various types of RFA applications in only the patients who were with SRMs, had the high anesthetical and also surgical risk and thus could not undergo any curative surgical treatment alternatives, genereal anesthesia, or the anesthesia with a long duration and to present the urologists’ experience in RFA treatment with the follow-up data of initial six months in this specific. In our study, different RFA techniques including USG-PRFA (9/12), CT-PRFA (1/12), R-LRFA (1/12) and T-LRFA (1/12) were used, and it was seen that the majority of RFA applications consisted of USG-PRFA application (75%). The amounts of various RFA groups were not appropriate for comparing their results, thus we just presented the overall results. The techical success rate of initial RFA application, which was accepted as the absence of an enhancing area inside the ablated tumor field, has been previously reported 90-100%. In our
mediated. In conclusion, although surgical management is still accepted as the gold-standard treatment for SRMs, RFA has become an effective and safe treatment alternative especially for T1 stage renal masses. Recent advancements in imaging modalities and technological and technical developments have resulted in similar functional and oncological outcomes of RFA to the surgical management. RFA is an increasingly popularity, ablative treatment modality, which presents some advantages of lower surgical and anesthesiological complication rates, shorter recovery time and hospital stay, no renal ischemia, and a curative, nephron sparing treatment choice to the patients who are not appropriate candidate for the surgery or do not prefer the surgical treatment. Thus, RFA can be a good choice of treatment with its lower surgical risk and similar oncological and functional results comparable with the surgical treatment of SRMs. However, our study showed that RFA seemed to be a safe, effective, well tolerated and minimal invasive treatment in also the selected cases of small renal tumors with excessive anesthetical and also.

mediated. In conclusion, although surgical management is still accepted as the gold-standard treatment for SRMs, RFA has become an effective and safe treatment alternative especially for T1 stage renal masses. Recent advancements in imaging modalities and technological and technical developments have resulted in similar functional and oncological outcomes of RFA to the surgical management. RFA is an increasingly popularity, ablative treatment modality, which presents some advantages of lower surgical and anesthesiological complication rates, shorter recovery time and hospital stay, no renal ischemia, and a curative, nephron sparing treatment choice to the patients who are not appropriate candidate for the surgery or do not prefer the surgical treatment. Thus, RFA can be a good choice of treatment with its lower surgical risk and similar oncological and functional results comparable with the surgical treatment of SRMs. However, our study showed that RFA seemed to be a safe, effective, well tolerated and minimal invasive treatment in also the selected cases of small renal tumors with excessive anesthetical and also.

mediated. In conclusion, although surgical management is still accepted as the gold-standard treatment for SRMs, RFA has become an effective and safe treatment alternative especially for T1 stage renal masses. Recent advancements in imaging modalities and technological and technical developments have resulted in similar functional and oncological outcomes of RFA to the surgical management. RFA is an increasingly popularity, ablative treatment modality, which presents some advantages of lower surgical and anesthesiological complication rates, shorter recovery time and hospital stay, no renal ischemia, and a curative, nephron sparing treatment choice to the patients who are not appropriate candidate for the surgery or do not prefer the surgical treatment. Thus, RFA can be a good choice of treatment with its lower surgical risk and similar oncological and functional results comparable with the surgical treatment of SRMs. However, our study showed that RFA seemed to be a safe, effective, well tolerated and minimal invasive treatment in also the selected cases of small renal tumors with excessive anesthetical and also.

mediated. In conclusion, although surgical management is still accepted as the gold-standard treatment for SRMs, RFA has become an effective and safe treatment alternative especially for T1 stage renal masses. Recent advancements in imaging modalities and technological and technical developments have resulted in similar functional and oncological outcomes of RFA to the surgical management. RFA is an increasingly popularity, ablative treatment modality, which presents some advantages of lower surgical and anesthesiological complication rates, shorter recovery time and hospital stay, no renal ischemia, and a curative, nephron sparing treatment choice to the patients who are not appropriate candidate for the surgery or do not prefer the surgical treatment. Thus, RFA can be a good choice of treatment with its lower surgical risk and similar oncological and functional results comparable with the surgical treatment of SRMs. However, our study showed that RFA seemed to be a safe, effective, well tolerated and minimal invasive treatment in also the selected cases of small renal tumors with excessive anesthetical and also.
Radiofrequency Ablation Treatment of Small Renal Tumors in Patients at High Anesthetic and Surgical Risk


References